The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...

After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | ...

But the YoY growth is expected to decline for the Indian Pharmaceutical Market (IPM), projected at approximately 8 per cent, ...

Managers face a variety of challenges during their careers. Instead of falling into fight or flight, develop resilience to ...

The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had ...